Introduction to a Clinical Course On New Developments In Atopic Dermatitis
Atopic Dermatitis
Program Overview
Atopic dermatitis: burden and impact
Atopic Dermatitis: Clinical Presentation
Psychological Burden of Skin Diseases: Atopic Dermatitis
Atopic Dermatitis: Current Management Options
Current Management: Moderate to Severe Atopic Dermatitis
Case of a Woman With Lifelong History of Atopic Dermatitis
Concluding Remarks
Characterizing atopic dermatitis: going beneath the skin
Introduction
Nonlesional Skin in Atopic Dermatitis Shows Abnormal Cytokine Profile
Paradigm Shift in the Pathogenesis of Atopic Dermatitis
Same Pathways in Adults and Children?
Pediatric vs Adult Skin in Atopic Dermatitis
Test of Immune Hypothesis With Dupilumab
Patients on Higher Doses Achieved EASI-50
Reduction in Epidermal Hyperplasia After 4 Weeks of Dupilumab Treatment
Suppression of Th2 and Other Axes
Other Targets in Clinical Trials for Atopic Dermatitis
Concluding Remarks
Setting standards in atopic dermatitis management
Treatment Guidelines and Recommendations for Atopic Dermatitis
Measuring Disease Activity: ETFAD
Treatment Options by Grade of Atopic Dermatitis
Systemic Immunosuppressants for Severe Atopic Dermatitis
Treatment Options for Moderate Atopic Dermatitis
Concluding Remarks
Biological therapy for atopic dermatitis: new developments
Introduction
Role of Th2 in Atopic Dermatitis
SOLO 1 and 2 Phase 3 Results: Dupilumab
SOLO 1 and 2 Phase 3 Results: Depression Scores
Interaction With Many Pathways: Example of Cyclosporine
SOLO 1 and 2: Safety and Tolerability
Dupilumab in Asthma and Nasal Polyps
Other Targets in Clinical Trials for Atopic Dermatitis
Atopic Dermatitis and Comorbidities
Patient Case of Severe Atopic Dermatitis
Looking into the future: emerging therapeutic pathways in atopic dermatitis
Novel Developments in the Understanding of Atopic Dermatitis
Future Potential of New Biologic Therapies
Importance of Restoring Barrier Function
Concluding Remarks
Abbreviations
Abbreviations